Resistance-associated variants in HCV subtypes 1a and 1b detected by Ion Torrent sequencing platform

Antiviral Therapy

Volumn 21, Issue 8, 2016, Pages 653-660

  Gaspareto, Karine V ^a   Ribeiro, Roberto M ^a   De Mello Malta, Fernanda ^a   Gomes Gouvêa, Michele S ^a   Muto, Nair H ^b   Romano, Camila M ^a   Mendes Correa, Maria C ^a   Carrilho, Flair J ^a   Sabino, Ester C ^a   Rebello Pinho, João R ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ASUNAPREVIR; BOCEPREVIR; DACLATASVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NS4 PROTEIN, HEPATITIS C VIRUS; VIRAL PROTEIN;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; BRAZIL; CHRONIC HEPATITIS C; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 1A; HEPATITIS C VIRUS GENOTYPE 1B; HUMAN; INFORMED CONSENT; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POPULATION RESEARCH; REAL TIME POLYMERASE CHAIN REACTION; VIRUS LOAD; CLASSIFICATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION;

ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; FEMALE; HEPACIVIRUS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85011298853     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP3057     Document Type: Article

References (47)

1. Roelandt P, Obeid S, Paeshuyse J, et al. Human pluripotent stem cell-derived hepatocytes support complete replication of hepatitis C virus. J Hepatol 2012; 57:246-251.
2. Qi H, Wu NC, Du Y, Wu TT, Sun R. High-resolution genetic profile of viral genomes: why it matters. Curr Opin Virol 2015; 14:62-70.
3. US Food and Drug Administration. FDA news release. FDA approves Victrelis for hepatitis C. (Updated 23 May 2011. Accessed 2 December 2015.) Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm255390.htm
4. US Food and Drug Administration. FDA news release. FDA approves Incivek for hepatitis C. (Updated 23 May 2011. Accessed 2 December 2015.) Available from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm256299.htm
5. Flamm SL, Lawitz E, Jacobson I, et al. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection. Clin Gastroenterol Hepatol 2013; 11:81-87.e84.
6. Kieffer TL, De Meyer S, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE 2012; 7:e34372.
7. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63:199-236.
8. Perry CM. Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C. Drugs 2012; 72:619-641.
9. Poordad F, McCone J, Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-1206.
10. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011; 17:122-134.
11. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373:2608-2617.
12. Cuypers L, Li G, Libin P, Piampongsant S, Vandamme AM, Theys K. Genetic diversity and selective pressure in hepatitis C virus genotypes 1-6: significance for direct-acting antiviral treatment and drug resistance. Viruses 2015; 7:5018-5039.
13. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373:2599-2607.
14. Gane EJ, Roberts SK, Stedman CA, et al. Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2010; 376:1467-1475.
15. Zeuzem S, Buggisch P, Agarwal K, et al. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology 2012; 55:749-758.
16. Vandamme AM, Camacho RJ, Ceccherini Silberstein F, et al. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011; 13:77-108.
17. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146:1176-1192.
18. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64:486-504.
19. Garson JA, Ring C, Tuke P, Tedder RS. Enhanced detection by PCR of hepatitis C virus RNA. Lancet 1990; 336:878-879.
20. Rothberg JM, Hinz W, Rearick TM, et al. An integrated semiconductor device enabling non-optical genome sequencing. Nature 2011; 475:348-352.
21. Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30:434-439.
22. Applegate TL, Gaudieri S, Plauzolles A, et al. Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C. Antivir Ther 2015; 20:199-208.
23. Lenz O, Fevery B, Verbinnen T, et al. Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies. Hepatology 2013; 58:793A.
24. Jacobson I, Dore GJ, Foster GR. Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naive patients: results from QUEST-1, a Phase III trial. J Hepatol 2013; 58 Suppl 1:S574.
25. Lisboa-Neto G, Noble CF, Pinho JR, et al. Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection. Antivir Ther 2014; 20:281-287.
26. Sølund C, Krarup H, Ramirez S, et al. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations. PLoS ONE 2014; 9:e113034.
27. Hoffmann L, Faffe DS, Lima JF, et al. No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy. BBA Clin 2015; 3:146-151.
28. Uchida Y, Kouyama JI, Naiki K, et al. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol 2016; 51:260-270.
29. Yoshimi S, Imamura M, Murakami E, et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol 2015; 87:1913-1920.
30. U.S. Food and Drug Administration news release. FDA approves Zepatier for hepatitis C. (Accessed 25 February 2016.) Available from http://www:accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails.
31. Forns X, Gordon SC, Zuckerman E, et al. Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 2015; 63:564-572.
32. Pawlotsky JM. Hepatitis C virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology 2016; 151:70-86.
33. Paolucci S, Fiorina L, Mariani B, et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 2013; 10:355.
34. Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015; 61:56-65.
35. Pol S, Sulkowski MS, Hassanein T, et al. Sofosbuvir plus pegylated interferon and ribavirin in patients with genotype 1 hepatitis C virus in whom previous therapy with direct-acting antivirals has failed. Hepatology 2015; 62:129-134.
36. Chulanov V, Zhdanov K, Kersey K. Sofosbuvir plus ribavirin for the treatment of Russian patients with chronic HCV genotype 1 or 3 infection. 65th Annual Meeting of the American Association for the Study of Liver Disease (AASLD). Boston, MA, USA. 7-11 November 2014. Abstract 982.
37. Margeridon-Thermet S, Le Pogam S, Li L, et al. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing. PLoS ONE 2014; 9:e105569.
38. Aissa Larousse J, Trimoulet P, Recordon-Pinson P, et al. Natural prevalence of hepatitis C virus (HCV) variants resistant to protease and polymerase inhibitors in patients infected with HCV genotype 1 in Tunisia. J Med Virol 2014; 86:1350-1359.
39. Di Maio VC, Cento V, Mirabelli C, et al. Hepatitis C virus genetic variability and the presence of NS5B resistance-associated mutations as natural polymorphisms in selected genotypes could affect the response to NS5B inhibitors. Antimicrob Agents Chemother 2014; 58:2781-2797.
40. Ribeiro RM, Li H, Wang S, et al. Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog 2012; 8:e1002881.
41. Fourati S, Pawlotsky JM. Virologic tools for HCV drug resistance testing. Viruses 2015; 7:6346-6359.
42. Capobianchi MR, Giombini E, Rozera G. Next-generation sequencing technology in clinical virology. Clin Microbiol Infect 2013; 19:15-22.
43. Bartels DJ, Sullivan JC, Zhang EZ, et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. J Virol 2013; 87:1544-1553.
44. Dietz J, Susser S, Berkowski C, Perner D, Zeuzem S, Sarrazin C. Consideration of viral resistance for optimization of direct antiviral therapy of hepatitis C virus genotype 1-infected patients. PLoS ONE 2015; 10:e0134395.
45. Sarrazin C, Lathouwers E, Peeters M, et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res 2015; 116:10-16.
46. Fridell RA, Wang C, Sun JH, et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 2011; 54:1924-1935.
47. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle B, McCarville JF, Pang PS. Baseline and post-baseline resistance analyses of Phase 2/3 studies of ledipasvir/sofosbuvir +/- RBV. Hepatology 2014; 60:1128a.